Accelerating gene therapy downstream process development through DoE and scalable chromatography

In the competitive landscape of gene therapy development, achieving efficient purification workflows is crucial for success. This Executive Summary delves into how the design of experiments (DoE) methodology can streamline downstream process development (PD), specifically for AAV therapies, and how pre-packed chromatography columns play a key role in this process.

Please enter your email to access content Read now